Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultra-low dose CT could slash radiation for HHT lung checks

NCT ID NCT04108052

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether an ultra-low dose chest CT scan can find lung blood vessel malformations in people with hereditary hemorrhagic telangiectasia (HHT) as well as the standard low-dose CT scan, but with much less radiation. 45 HHT patients received both scans, and radiologists compared the results. The goal is to reduce the radiation exposure from repeated lifetime scans without missing dangerous malformations that can cause strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultra-low dose CT scan (radiation)
What this could lead to
If successful, this could allow HHT patients to get safer, lower-radiation lung scans for routine monitoring.
What could go wrong
This is a small, completed study with only 45 participants. The ultra-low dose images may be too noisy to reliably detect small malformations, limiting its use in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Nov 2019

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient monitored for a clinically confirmed Rendu-Osler disease and / or confirmed by molecular biology, seen for an initial assessment or for a reassessment of PAVM (after treatment or without treatment) * Patient who agreed to participate in the study and signed the written informed consent * Patient affiliated to a social security scheme or similar Exclusion Criteria: * Women who are pregnant, nursing (lactating) or at risk of pregnancy (verified by a urine test before performing the scanner) * Patient who is protected adults under the terms of the law (French Public Health Code). * Patient who has not or poorly understand French

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rendu osler disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arteriovenous hemangioma/malformation disease hereditary hemorrhagic telangiectasia Pulmonary Arteriovenous Fistulas

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rendu osler disease Telangiectasia, hereditary hemorrhagic

Contacts and locations

Locations

  • Hospices Civils de Lyon - Hopital Louis Pradel

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.